glp-1-directed nmda receptor antagonism for obesity treatment Eric Topol on X: "The GLP-1 family of drugs have exceeded all expectations, beyond diabetes and obesity. Now there's a pre-clinical GLP-1 and dual drug with many enhanced features that GLP1 Receptor Agonists—Effects beyond Obesity
Pay in 4 interest-free payments of $7.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28


























